MARKET

CRVS

CRVS

Corvus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.650
+0.080
+3.11%
Opening 11:12 04/21 EDT
OPEN
2.560
PREV CLOSE
2.570
HIGH
2.670
LOW
2.555
VOLUME
29.98K
TURNOVER
--
52 WEEK HIGH
6.88
52 WEEK LOW
2.120
MARKET CAP
101.52M
P/E (TTM)
-12.6010
1D
5D
1M
3M
1Y
5Y
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 1d ago
Tyrosine Protein Kinase ITK Market 2021 is Booming by Leading key Players - Forecast 2026 | Arrien Pharmaceuticals LLC, Confluence Life Sciences Inc
Market Insight Reports · 04/07 17:28
Global Tyrosine Protein Kinase ITK Market Outlook by Key Players, Size, Share, Industry Overview, Supply and Consumption Demand Analysis By 2027
Apr 05, 2021 (The Expresswire) -- Global "Tyrosine Protein Kinase ITK Market" Research Report features an extensive study of the current market landscape and...
The Express Wire · 04/05 08:43
DJ Corvus Pharmaceuticals Price Target Cut to $9.50/Share From $12.00 by HC Wainwright & Co.
Dow Jones · 03/26 10:33
DJ Corvus Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/26 10:33
Corvus Pharmaceuticals (CRVS) Gets a Hold Rating from Mizuho Securities
In a report released today, Mara Goldstein from Mizuho Securities maintained a Hold rating on Corvus Pharmaceuticals (CRVS), with a price target of $4.00.
SmarterAnalyst · 03/25 15:35
8-K: Corvus Pharmaceuticals, Inc.
(EDGAR Online via COMTEX) -- 0001626971 False 0001626971 2021-03-25 2021-03-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 03/25 15:29
10-K: CORVUS PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion should be...
Edgar Online - (EDG = 10Q, 10K) · 03/25 13:20
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRVS. Analyze the recent business situations of Corvus Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRVS stock price target is 6.50 with a high estimate of 9.50 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 70
Institutional Holdings: 19.84M
% Owned: 51.78%
Shares Outstanding: 38.31M
TypeInstitutionsShares
Increased
7
257.93K
New
7
264.02K
Decreased
13
1.18M
Sold Out
6
209.64K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.48%
Pharmaceuticals & Medical Research
+0.93%
Key Executives
Chairman/President/Chief Executive Officer/Director
Richard Miller
Chief Financial Officer/IR Contact Officer
Leiv Lea
Senior Vice President
Daniel Hunt
Senior Vice President
William Jones
Vice President
Mehrdad Mobasher
Vice President
Erik Verner
Director
Edith Mitchell
Independent Director
Ian Clark
Independent Director
Elisha Gould
Independent Director
Linda Grais
Independent Director
Steve Krognes
Independent Director
Scott Morrison
Independent Director
Peter Thompson
No Data
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

Webull offers kinds of Corvus Pharmaceuticals Inc stock information, including NASDAQ:CRVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRVS stock methods without spending real money on the virtual paper trading platform.